효모의 수용성 글루칸 올리고머를 함유하는 항 H1N2형 조류독감 바이러스제
    32.
    发明授权
    효모의 수용성 글루칸 올리고머를 함유하는 항 H1N2형 조류독감 바이러스제 失效
    含有酵母可溶性葡聚糖寡聚体的抗H1N1禽流感病毒

    公开(公告)号:KR100485056B1

    公开(公告)日:2005-04-22

    申请号:KR1020040003621

    申请日:2004-01-19

    Abstract: Provided is an anti-H1N2 type viral composition comprising a soluble glucan oligomer of Saccharomyces cerevisiae. The soluble glucan oligomer of Saccharomyces cerevisiae is useful for inhibition of porcine influenza virus having gene fragments of bird influenza virus. The anti-H1N2 type viral composition comprises soluble glucan oligomer of Saccharomyces cerevisiae having molecular weight of 50,000 dalton or less as an effective component. The method for preparing the soluble glucan oligomer of Saccharomyces cerevisiae comprises the steps of: (a) culturing a Saccharomyces cerevisiae mutant IS2(KCTC 0959BP) in a broth medium for inoculation; (b) inoculating the cultured medium of Saccharomyces cerevisiae mutant IS2(KCTC 0959BP) into the broth medium, fed-batch culturing the microorganism and centrifuging the cultured medium to obtain Saccharomyces cerevisiae mutant IS2(KCTC 0959BP); (c) adding NaOH into the Saccharomyces cerevisiae mutant IS2(KCTC 0959BP) obtained to extract beta-glucan from the cellular membrane of the Saccharomyces cerevisiae mutant IS2(KCTC 0959BP); (d) reacting the extracted beta-glucan with a beta-glucanase, and filtering the reaction product to prepare the soluble glucan oligomer; and (e) freeze-drying the soluble glucan oligomer to obtain soluble glucan oligomer powder.

    에스시탈로프람을 포함하는 허혈성 뇌질환 예방 또는 개선용 약학조성물
    39.
    发明公开
    에스시탈로프람을 포함하는 허혈성 뇌질환 예방 또는 개선용 약학조성물 无效
    用于预防或改善含有ESCITALOPRAM的异常脑疾病的药理学组合物

    公开(公告)号:KR1020100054452A

    公开(公告)日:2010-05-25

    申请号:KR1020080113389

    申请日:2008-11-14

    Abstract: PURPOSE: A pharmaceutical composition containing escitalopram is provided to prevent neural cell damage in a CA1 area and to prevent or treat ischemic brain diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating ischemic a brain disease contains escitalopram. Ischemic brain disease is thrombosis, embolism, transient ischemic attack, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, white matter dyslipidemia, or lacune. The administering of escitalopram prevents or treats ischemic brain diseases. A pharmaceutical composition for preventing or treating brain disease contains escitalopram and a pharmaceologically acceptable carrier or excipient. The pharmaceutically acceptable carrier or excipient is water, dextrin, or a saline solution. The composition is used in the form of plasters, granules, lotions, powders, syrups, liquids and solutions, aerosols, ointments, fluid extract, emulsion, suspensions, infusions, tablets, injections, capsules, or pills.

    Abstract translation: 目的:提供含有依他普仑的药物组合物,以防止CA1区域的神经细胞损伤,并预防或治疗缺血性脑病。 构成:用于预防或治疗缺血性脑病的药物组合物含有依他普仑。 缺血性脑病是血栓形成,栓塞,短暂性脑缺血发作,脑梗塞,脑出血,蛛网膜下腔出血,白质血脂异常,或泪液。 依他普仑的给药预防或治疗缺血性脑病。 用于预防或治疗脑疾病的药物组合物含有依他普仑和药物学上可接受的载体或赋形剂。 药学上可接受的载体或赋形剂是水,糊精或盐水溶液。 组合物以膏药,颗粒剂,洗剂,粉剂,糖浆,液体和溶液,气溶胶,软膏,流体萃取物,乳液,悬浮液,输液,片剂,注射剂,胶囊或丸剂的形式使用。

Patent Agency Ranking